Printvenlig
Sitemap
Board of Directors
The Thrombologic Board has five members, including an independent specialist and the Senior Doctor who first invented the therapy that Thrombologic is aiming to develop.
Stephan Christgau (Chairman of the Board)
Investment Director at Novo Seeds
Jens Kindtler
Head of Tectra at Copenhagen University Hospital (Riget)
Jens read civil engineering (biochemistry and molecular biology) at Denmark’s Technical University. He has an MBA from Henley Management College, UK, and is a qualified Patent Agent. He is a partner in BankInvest Biomedical Venture – and has previously worked for Novo Nordisk, Ferrosan CNS Division and the Carlsberg Research Centre.
Leif Helth Jensen
Leif Helth Jensen has more than 28 years’ experience within the life science industry. He has been the CEO of two biotech companies, on the Board of six, and co-founded four others. He is currently on the Board of Directors of Inagen ApS, Alcorlab ApS and Rose Pharma A/S – and is the Chairman of the Board at Bone Medical Ltd., Valderm A/S, Serendex ApS, Microlytics A/S, Synome Ltd., Dencore ApS and Global Aviation A/S.
Leif has a M.Sc. in biology from the University of Copenhagen. He is the co-author of more than 35 peer-reviewed scientific papers and a co-inventor of 19 patent families.
Per Sprøgel
Vice President, International Clinical Development, LEO Pharma
Per has a degree in medicine and held a hospital position before moving into the pharmaceutical industry. He has since had a number of positions at LEO Pharma related to medical and clincal tasks at various levels and is now responsible for LEO Pharmas Clinical Development department. Per has specific experience in the area of thrombosis and critical care.
Pär I. Johansson
The inventor of the idea that Thrombologic is building on, Pär is a specialist in anesthesiology, clinical immunology and transfusion medicine. His research focuses on the interplay between the haemostatic, inflammatory and innate immune systems in critical illness and trauma.
Pär has published more than 80 peer-reviewed scientific manuscripts and he is a member of several international research collaborations. He is also Chairman of the International Symposium on Critical Bleeding.
Management
Chief Executive Officer
Karolina Rask
Before taking over at Thrombologic, Karolina was responsible for managing Phase I/II oncology clinical trials for Genmab in Copenhagen, investigating a fully human monoclonal antibody. She has also held positions at Mitsubishi Pharma Europe in London, Icon Clinical Research in Stockholm, Nuevolution in Copenhagen, and as a molecular biologist at Rockefeller University in New York City.
Karolina has a Master’s degree in biomedicinal chemistry from the University of Kalmar in Sweden.
Vice President Business Development
Nancy J. Levy
Nancy has been on the faculty at Harvard Medical School, where she did her fellowship. She earned her Ph.D from the University of Chicago. She has worked with a range of clients from pre-IPO to mid-market companies and from venture capitalists to investment bankers. At Millenium Pharmaceuticals, she established successful collaborations with alliance partner Genentech to move a Phase II product with potential first drug indication towards the market.